Subscribe To
AIM / FDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic Cancer
Content Topics
Removes
Clinical
Hold
Immunotech
Mid
Stage
Ampligen
Trial
Immunotech s
Mid stage
Pancreatic
Cancer
Stock
AIM
AIM News
By GlobeNewsWire
September 22, 2023
AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAlee more_horizontal
By GlobeNewsWire
September 5, 2023
AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
OCALA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas more_horizontal
By GlobeNewsWire
August 9, 2023
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
OCALA, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that manageme more_horizontal
By GlobeNewsWire
June 14, 2023
AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
OCALA, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company fo more_horizontal
By GlobeNewsWire
March 27, 2023
AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast
OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company fo more_horizontal
By Proactive Investors
January 9, 2023
AIM ImmunoTech broadens patent portfolio with new Netherlands utility patent
AIM ImmunoTech Inc (NYSE:AIM) has announced that the Netherlands Patent Office has granted the company a utility patent covering rugged dsRNA, a doubl more_horizontal
By Proactive Investors
December 12, 2022
AIM ImmunoTech promotes Christopher McAleer to the role of scientific officer
AIM ImmunoTech Inc (NYSE:AIM) has announced the promotion of Christopher McAleer from the company's deputy scientific officer to the position of scien more_horizontal
By Proactive Investors
December 8, 2022
AIM ImmunoTech reports positive safety, tolerability, and biological activity data from Phase 1 Ampligen study
AIM ImmunoTech Inc (NYSE:AIM) has reported positive safety, tolerability, and biological activity data from a Phase 1 study involving the intranasal a more_horizontal